Breast cancer therapies: Increasing costs in the age of targeted therapies. An unethical discussion? Mammakarzinomtherapie: Kostenentwicklung im zeitalter zielgerichteter therapien: Eine anstößige Diskussion?
Mundhenke C, Schem C, Weigel M, Strauss A (2010)
Publication Type: Journal article
Publication year: 2010
Journal
Book Volume: 43
Pages Range: 1008-1010
Journal Issue: 12
DOI: 10.1007/s00129-010-2645-y
Abstract
Targeted therapies lead to increased costs in the treatment of breast cancer patients. In Germany hardly any cost analyses for these substances have been performed. Here studies from different countries are cited, although their health systems might differ from the German system significantly. Therefore, these cost analysis have mainly an orientating character. Trastuzumab is part of adjuvant standard regimen when HER-2/neu is overexpressed. A Swiss analysis showed cost efficiency, especially for follow-ups >10 years. In HER-2/neu-positive metastatic breast cancer (MBC), a French evaluation also found trastuzumab to be cost efficient in this indication. The National Institute for Health and Clinical Excellence (UK) reported lapatinib, which also inhibits HER-2/neu, in combination with capecitabine in MBC was not considered to be cost efficient. In addition, a critical Swiss cost analysis did not find cost efficiency for bevacizumab combined with paclitaxel in MBC. In Germany, guidelines to evaluate cost efficiency of new innovative targeted therapies are lacking. In times of limited financial resources in the health system, an active public discussion about costs and cost efficiency of new drugs is necessary. © Springer-Verlag 2010.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Mundhenke, C., Schem, C., Weigel, M., & Strauss, A. (2010). Breast cancer therapies: Increasing costs in the age of targeted therapies. An unethical discussion? Mammakarzinomtherapie: Kostenentwicklung im zeitalter zielgerichteter therapien: Eine anstößige Diskussion? Gynäkologe, 43(12), 1008-1010. https://doi.org/10.1007/s00129-010-2645-y
MLA:
Mundhenke, Christoph, et al. "Breast cancer therapies: Increasing costs in the age of targeted therapies. An unethical discussion? Mammakarzinomtherapie: Kostenentwicklung im zeitalter zielgerichteter therapien: Eine anstößige Diskussion?" Gynäkologe 43.12 (2010): 1008-1010.
BibTeX: Download